Page last updated: 2024-09-02

ramosetron and Breast Neoplasms

ramosetron has been researched along with Breast Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baek, SH; Baik, SW; Kim, CH; Kim, HK; Kim, KH; Kwon, JY; Lee, HJ; Shin, SW1
Hojo, S; Noguchi, S; Shiba, E; Taguchi, T; Takamura, Y; Tsukamoto, F; Watanabe, T; Yoneda, K1

Trials

2 trial(s) available for ramosetron and Breast Neoplasms

ArticleYear
Preoperatively administered ramosetron oral disintegrating tablets for preventing nausea and vomiting associated with patient-controlled analgesia in breast cancer patients.
    European journal of anaesthesiology, 2008, Volume: 25, Issue:9

    Topics: Administration, Oral; Adult; Analgesia, Patient-Controlled; Analgesics, Opioid; Antiemetics; Benzimidazoles; Breast Neoplasms; Female; Fentanyl; Humans; Middle Aged; Pain Measurement; Patient Satisfaction; Postoperative Nausea and Vomiting; Premedication; Serotonin Antagonists; Treatment Outcome

2008
[Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:8

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Appetite; Benzimidazoles; Breast Neoplasms; Breast Neoplasms, Male; Cisplatin; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Nausea; Safety; Serotonin Antagonists; Treatment Outcome; Vomiting

1999